Depression and Anxiety Trial, Recruiting NCT05897021 Sponsor: VA Office of Research and Development Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT05897021
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are Veterans and identify as a sexual minority (such as gay, lesbian, bisexual, pansexual, queer, or any identity other than heterosexual)
  • People whose depression or anxiety symptoms score above a certain level on standard questionnaires (the PHQ-9 or GAD-7)
  • People who have experienced stressful events related to their sexuality that are contributing to their current distress, as confirmed during a phone screening
  • People who are taking psychiatric medications must have been on a stable dose for at least 4 weeks before joining

Who may not be able to join:

  • People who currently have a specific plan and/or intent to end their life, as assessed using a standard scale called the Columbia Suicide Severity Rating Scale
  • People who are currently experiencing unstable mania or psychosis, as assessed through a structured clinical interview
  • People who currently have a severe substance use disorder, as assessed through a structured clinical interview
  • People with significant cognitive difficulties, including those with moderate or severe traumatic brain injury, where the level of difficulty makes it hard to understand the screening questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kelly L Harper, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Phone: (857) 364-4417

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 March 2024
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Feasibility of the Expressive Writing on Minority Stressors (EWMS) intervention; Patient satisfaction with the Expressive Writing on Minority Stressors (EWMS) intervention

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov